Familial Hypercholesterolemia Clinical Trials 2024

Familial Hypercholesterolemia Clinical Trials 2024

Familial Hypercholesterolemia research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in sjia clinical trials today.

Popular filter options for Familial Hypercholesterolemia trials

Hypercholesterolemia Clinical Trials

View 13 Hypercholesterolemia medical studies.

High Cholesterol Clinical Trials

View 7 High Cholesterol medical studies.

Phase 3 Familial Hypercholesterolemia Clinical Trials

View 13 phase 3 familial hypercholesterolemia medical studies.

Familial Hypercholesterolemia Clinical Trials With No Placebo

View 13 familial hypercholesterolemia medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to Familial Hypercholesterolemia

What are the top hospitals conducting Familial Hypercholesterolemia research?

Familial Hypercholesterolemia (FH), a hereditary condition characterized by abnormally high levels of cholesterol, is being tackled head-on by top hospitals conducting pioneering clinical trials. Among them is the Novartis Investigative Site in Boca Raton, where three active FH trials are currently underway—the first of which was recorded as recently as 2021. In Port Orange, Progressive Medical Research (Site 0021) leads with one ongoing FH trial and a history of one completed trial since their initiation into FH research in 2023. Similarly, Velocity Clinical Research at The Pioneer Heart Institute in Lincoln (Site 0026) also joins the ranks with one active FH trial and an equally impressive single previous study dating back to 2023.

Meanwhile, Jubilee Clinical Research in Las Vegas (Site 0030) and Velocity Clinical Research located in Salt Lake City (Site 0004) are making significant contributions to understanding and combating this genetic disorder through their respective active trials—both marking their first recorded investigations into Familial Hypercholesterolemia also starting from the year 2023.

These hospitals' commitment to advancing our knowledge of FH not only offers hope for those affected by this condition but also highlights the importance of targeted research efforts across different locations. By participating in these clinical trials, patients have access to innovative treatments that could potentially revolutionize how we manage familial hypercholesterolemia—an invaluable step toward improving lives impacted by high cholesterol levels passed down through generations.

Which are the best cities for Familial Hypercholesterolemia clinical trials?

Boca Raton, Florida emerges as a top city for Familial Hypercholesterolemia clinical trials with 5 active studies investigating treatments like Inclisiran and MK-0616. Philadelphia, Pennsylvania follows closely behind with 3 ongoing trials focused on various interventions, including Penn Medicine-mediated research and Inclisiran. Cincinnati, Ohio also shows promise in the field with 3 active trials studying Inclisiran and ARO-ANG 3 Injection. These cities provide individuals affected by Familial Hypercholesterolemia access to cutting-edge clinical trials that hold potential for advancing treatment options and improving patient outcomes.

Which are the top treatments for Familial Hypercholesterolemia being explored in clinical trials?

Clinical trials are paving the way for new treatments in the battle against Familial Hypercholesterolemia. One standout contender is inclisiran, currently being explored in three active trials specifically targeting this condition. Since its introduction in 2017, it has been featured in a total of six clinical trials dedicated to Familial Hypercholesterolemia. Another promising treatment on the horizon is MK-0616, which made its debut just last year and already boasts one ongoing trial and three all-time studies focused on combating this inherited disorder. These innovative therapies offer hope for individuals living with Familial Hypercholesterolemia and may potentially revolutionize their management of cholesterol levels.

What are the most recent clinical trials for Familial Hypercholesterolemia?

Exciting advancements are occurring in the field of Familial Hypercholesterolemia (FH), offering hope for those affected by this genetic disorder. Recent clinical trials have investigated several potential treatments, including 2-Hydroxybenzylamine (2-HOBA) and MK-0616. These medications have shown promise in managing FH by targeting cholesterol levels and reducing cardiovascular risks. Additionally, studies have explored the efficacy of Evinacumab and Inclisiran as treatments for FH, with promising results emerging from Phase 3 trials. The ARO-ANG 3 Injection has also been evaluated in Phase 2 trials, further expanding the range of therapeutic options available to individuals living with FH. With ongoing research efforts focused on developing effective interventions, a brighter future may be within reach for those impacted by this condition.

What Familial Hypercholesterolemia clinical trials were recently completed?

In the realm of Familial Hypercholesterolemia, several notable clinical trials have recently reached completion, showcasing important advancements in this field. In March 2022, Merck Sharp & Dohme Corp. concluded a trial for MK-0616, while Regeneron Pharmaceuticals completed their Evinacumab study in June 2020. Additionally, LIB Therapeutics LLC's lerodalcibep trial wrapped up in December 2019, and Novartis finalized its trials on Inclisiran Sodium in April 2019 and Inclisiran in April 2017 respectively. These groundbreaking research efforts offer hope to individuals affected by Familial Hypercholesterolemia as scientists strive towards improved treatments for this genetic condition characterized by high cholesterol levels.